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Summary
Background:  A  series  of  case—control  studies  have  been  conducted  to  investigate  the  associ-
ation between  blood  lipid  and  phlegm  turbidity  syndrome  of  angina  pectoris,  but  produced
inconsistent  results.
Objective:  We  performed  a  meta-analysis  to  determine  the  association  between  blood  lipid  and
phlegm turbidity  syndrome  of  angina  pectoris  more  precisely.
Methods:  Manual  screening  as  well  as  screening  of  the  China  National  Knowledge  Infrastruc-
ture (CNKI),  Chinese  Journal  full-text  database  (VIP),  Wanfang  database  (WF),  ScienceDirect,
Pubmed,  the  Cochrane  Library,  and  Embase  were  carried  out  for  relevant  literature.  The
formula was  translated  to  calculate  the  pooled  mean  value  and  standard  deviation  value.
The ‘‘Newcastle—Ottawa  Quality  Assessment  Scale:  Case—Control  Studies’’  (NOS)  was  taken
to assess  the  quality  of  the  included  studies.  The  Revman  5.2.6  software  provided  by  ‘‘The
Cochrane  Collaboration’’  was  used  to  analyze  the  collected  data.  The  subgroup  analysis  was
established  according  to  the  sample  size  proportion  between  the  test  group  and  the  control
group. Sensitivity  analysis  was  constructed  by  using  two  different  effect  models.  Besides,  a
funnel plot  was  created  to  analyze  potential  publication  bias.
Abbreviations: CNKI, China National Knowledge Infrastructure; VIP, Chinese Journal full-text database; WF,  Wanfang database; TC,
total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein-cholesterol; HDL-C, high-density lipoprotein-cholesterol; QYDS, Qi and
yin deﬁciency syndrome; YDS, Yang deﬁciency syndrome; CCS, Cold coagulating syndrome; HQDS, heart qi deﬁciency syndrome; QSS, Qi
stagnation syndrome; HBSS, heart blood stasis syndrome; AMI, acute myocardial infarction; CHD, coronary heart disease; TCM, Traditional
Chinese Medicine.
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Results:  No  statistically  meaningful  difference  existed  between  the  test  group  and  control  group
of total  cholesterol  (TC)  and  low-density  lipoprotein-cholesterol  (LDL-C)  in  non-Qi  and  yin  deﬁ-
ciency syndrome  (QYDS)  and  non-Yang  deﬁciency  syndrome  (YDS)  subgroup,  whereas  the  two
biotic indicators  in  the  test  group  were  higher  than  the  non-phlegm  syndrome  group  in  other  sub-
groups. Triglyceride  (TG)  in  phlegm  syndrome  group  showed  superior  to  non-phlegm  syndrome
group in  the  rest  subgroups  except  for  the  non-CCS  (Cold  coagulating  syndrome)-non-YDS  sub-
group. High-density  lipoprotein-cholesterol  (HDL-C)  levels  of  the  phlegm  group  were  lower  than
that of  the  non-phlegm  group  in  all  subgroups.
Conclusion:  When  comparing  with  Traditional  Chinese  Medicine  (TCM)  syndromes  of  asthenia
nature, such  as  YDS,  QYDS,  and  heart  qi  deﬁciency  syndrome),  the  levels  of  TG,  TC,  and  LDL-C
were higher  in  phlegm  turbidity  syndrome.  However,  for  sthenia  syndromes  such  as  Qi  stagnation
syndrome  (QSS),  heart  blood  stasis  syndrome  (HBSS),  and  CCS,  there  was  no  obvious  difference.
Furthermore,  HDL-C  levels  in  the  phlegm  turbidity  group  were  lower  than  those  of  the  non-phlegm
group. Nevertheless,  these  results  should  be  conﬁrmed  with  further  studies.
© 2014  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Selection  criteria
Eligible  research  should  meet  the  following  criteria:  (a)ntroduction
ngina  pectoris  is  caused  by  rapid,  transient  myocardial
schemia  and  hypoxia.1 It  is  generally  acknowledged  that
atients  with  angina  pectoris  have  the  risk  of  acute  myocar-
ial  infarction  (AMI)  and  sudden  death,  and  the  prognosis
epends  on  the  extent  of  coronary  artery  disease  and  heart
unction.1 The  incidence  of  angina  in  China  has  increased
ear  by  year.2,3 Moreover,  the  onset  age  has  become  much
ounger.4
Although  the  etiology  of  coronary  heart  disease  (CHD)
emains  indistinct,  the  cause  of  CHD  is  believed  to  be  multi-
actorial.  The  recommended  risk  factors  include:  systematic
onditions,  such  as  diabetes  mellitus,  hyperlipidemia,5—7
ypertension8,9;  the  inﬂammatory  biomarkers:  hs-CRP10,11;
abits  and  customs:  cigarette12,13 and  alcohol.14 TCM  also
as  records  on  this  subject.  Angina  pectoris  belongs  to
he  category  of  chest  obstruction  in  TCM.  It  is  believed
hat  the  occurrence  of  the  disease  has  been  associated
ith  the  invasion  of  pathogenic  cold,  eating  disorder,  emo-
ional  illness,  etc.15 Eating  lot  of  greasy  and  sweet  food
r  being  addicted  to  cigarette  and  alcohol  may  lead  to
ysfunction  of  the  spleen.15 So  that  phlegm  retention  is
athered  by  the  water  and  dampness.  In  TCM,  the  concept
f  phlegm  is  referred  to  as  the  resultant  of  metabolic  dis-
rders  of  the  body’s  water.  This  pathological  product  may
lock  blood  circulation,  inﬂuence  the  function  of  organs,
nd  cause  a  variety  of  complex  pathological  changes  in
he  body,  thus  leading  to  the  emergence  of  phlegm  syn-
rome.  Phlegm  syndrome  refers  to  the  symptoms  caused
y  the  stopping  of  phlegm.  Phlegm  blocks  the  arteries  and
eins  of  heart,  which  ultimately  leads  to  phlegm  syndrome
ausing  chest  obstruction.15 Hyperlipidemia  has  been  inves-
igated  to  be  associated  with  phlegm  syndrome  of  angina
ectoris,  but  the  consequences  are  contradictory.  Despite
he  fact  that  these  biomarkers  were  found  to  signiﬁcantly
ncrease  the  risk  of  phlegm  syndrome  of  angina  pectoris
n  some  studies,16—24 others  found  only  borderline  relation-
25,26hip  or  even  no  association. Therefore,  we  established
his  systematic  review  to  further  examine  the  relation-
hip  between  blood  lipid  with  phlegm  syndrome  of  angina
ectoris.
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dethods
rotocol  and  registration
ur  protocol  can  be  accessed  on  University  of  York  Centre  for
eviews  and  Dissemination  (http://www.crd.york.ac.uk/
rospero/),  the  registration  number  is:  CRD42013006687.
earch  methods
ata  sources
ccording  to  the  ‘‘Cochrane  Handbook  for  Systematic
eviews  of  Interventions’’  published  by  The  Cochrane  Col-
aboration,  we  screened  the  following  online  databases
long  with  manual  screening:  China  National  Knowledge
nfrastructure  (CNKI;  1979  —  January  2014),  Chinese  Journal
ull-text  database  (1989  —  January  2013),  Wanfang  database
1977  —  January  2013),  ScienceDirect  (1823—2014),  Pubmed
1950—2014),  the  Cochrane  Library  (1948—2014),  and
mbase  (2009—2014).  The  latest  search  was  performed  on
0  January  2014.
earch  strategies
he  following  terms:  ‘‘Coronary  heart  disease,’’  ‘‘angina,’’
‘phlegm,’’  ‘‘phlegm  syndrome’’  were  used  to  identify  all
elevant  studies.  When  screening  ScienceDirect  and  other
nglish  databases,  we  built  a  search  strategy  as  follows:  (a)
ngina;  (b)  phlegm  syndrome;  (c)  phlegm  Zheng;  (d)  phlegm
attern;  (e)  tan  zhuo;  (f)  a  in  all  ﬁelds;  (g)  b  in  all  ﬁelds;  (h)
 in  all  ﬁelds;  (i)  d  in  all  ﬁelds  (j)  e  in  all  ﬁelds;  (k)  g  ‘OR’  h
OR’  i  ‘OR’  j  ‘AND’  f.  For  CNKI  and  other  Chinese  databases
he  following  strategy  was  used:  (a)  CHD;  (b)  angina;  (c)
hlegm;  (d)  a  in  abstract;  (e)  b  in  abstract;  (f)  c  in  abstract;
e)  d  ‘OR’  e  ‘AND’  f.ase—control  studies;  (b)  participants  should  be  diagnosed
ith  angina  pectoris  (stable  and  unstable)  in  Western
edicine  and  chest  obstruction  in  TCM;  (c)  phlegm  syn-
rome  should  be  contained;  (d)  diagnosis  standard  must  be
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Table  1  Eligible  diagnosis  of  the  participants.
Western  medicine  diagnostic  criteria  (WMDC)
A. The  ‘‘Nomenclature  and  criteria  for  diagnosis  of  ischemic  heart  disease’’  published  by  the  World  Health  Organization
(WHO) in  1979.a
B.  Guidelines  for  the  management  of  patients  with  unstable  angina  and  non-st-segment  elevation  myocardial  infarction  (the
1999 versionb and  the  2007  versionc or  updated  ones).
C. The  diagnosis  and  treatment  recommendations  of  unstable  angina  (the  2000  versiond or  updated  ones).
D. Diagnosis  published  in  Internal  Medicine.e
TCM  diagnostic  criteria  (TCMDC)
A. Guidelines  established  for  clinical  research  of  Traditional  Chinese  New  Drug  (the  1990  version  and  the  2002  version).f
B.  Diagnosis  according  to  Chinese  Internal  Medicine.g,h
C.  The  syndrome  differentiation  standard  of  coronary  heart  disease  in  TCM.i
D.  Clinic  terminology  of  Traditional  Chinese  Medical  diagnosis  and  treatment  syndromes.j
a Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the joint international society and federation of
cardiology/World Health Organization task force on standardization of clinical nomenclature. Circ 1979; 59(3):607—609.
b ACC/AHA. Guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction. A
report of American college of cardiology/American heart association task force or practice guidelines. J Am Coll Cardiol 2000; 36(5):
970.
c ACC/AHA. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarc-
tion: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol.
2008 Jan 15;51(2):210—47.
d Cardiology Branch of Chinese Medical Society, Editorial Board of Chinese Journal of Cardiology. Diagnosis and treatment recommen-
dations of unstable angina. Chinese Journal Of Cardiology. 2000; 28:409—412.
e Ye XG, Lu ZY. Internal medicine. Beijing: People’s Medical Publishing House. 2006:272.
f Ministry of Health of the People’s Republic of China. Guidelines for clinical research of Traditional Chinese New Drug. Beijing: China
Medical Science and Technology Press, 2002: 41.
g Zhang BY, Dong JH, Zhou ZY. Chinese Internal Medicine. Shanghai: Shanghai Science and Technology Publishing House. 1985: 108—112.
h Zhou ZY. Chinese Internal Medicine. Beijing: China Press of Traditional Chinese Medicine, 2003: 37—140.
i Professional committee of cardiovascular disease of China Society of Integrated Traditional Chinese and Western Medicine. Syndrome
differentiation standard of coronary heart disease in TCM. Clinical Focus. 1991. 6(11): 520—521.
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cj National technical supervision administration. Clinic terminolog
Beijing: China Standards Press. 1997:23—30.
authoritative  (‘‘authoritative’’  means  the  diagnosis
standard  should  be  acknowledged  universally  or  generally
approved  over  the  country,  which  is  showed  in  Table  1);  (e)
providing  sufﬁcient  data  for  standardized  mean  difference
(SMD)  with  the  corresponding  95%  conﬁdence  interval  (CI);
(f)  investigating  the  association  between  blood  lipid  and
phlegm  syndrome  of  chest  obstruction.
Exclusion  criteria
The  exclusion  criteria  were:  (a)  no  control  group  set  in  the
documents,  (b)  unclear  original  data,  (c)  no  clearly  iden-
tiﬁed  result  assessment,  (d)  patients  with  acute  coronary
syndrome  (ACS),  (e)  unclear  or  overlapping  TCM  syndrome
type,  (f)  no  comparison  between  TCM  syndromes,  and  (g)
multiple  contributions  of  one  manuscript.
Data  collection  and  analysis
Data  extraction  and  management
After  ruling  out  unsatisfactory  literature  through  screening
the  title  and  abstract,  two  reviewers  then  read  the  full  text
to  assess  the  inclusion  standards  independently.  Any  dis-
agreement  was  resolved  through  discussion  or  third-party
opinions  on  the  basis  of  a  cross-check.
One  reviewer  took  a  standardized  electronic  data
collection  form  to  extract  data  while  a  subsequent
reviewer  checked  the  accuracy  separately.  When  necessary,
o
i
n
ctraditional Chinese medical diagnosis and treatment—–Syndromes.
dditional  information  was  sought  from  ﬁrst  or  correspond-
ng  authors  via  electronic  mail.
The  phlegm  turbidity  group  was  considered  as  the  exper-
mental  group  and  was  compared  with  the  non-phlegm
urbidity  group  which  was  considered  as  the  control  group.
e  found  that  the  non-phlegm  turbidity  group  was  divided
nto  subgroups  such  as  blood  stasis  syndrome,  qi  stagnation
yndrome  (QSS),  qi  deﬁciency  syndrome,  and  other  syn-
romes  to  collect  data  in  most  studies.  In  some  articles,
riginal  data  could  not  be  obtained  even  after  contacting
he  authors.  Therefore,  the  mean  value  and  standard  devia-
ion  value  for  each  subgroup  of  these  studies  were  combined
o  get  an  incorporated  mean  value  and  standard  deviation
alue.  The  derived  formula  is  calculated  by  formula  (a)  and
ormula  (b).27,28
ssessment  of  risk  of  bias  in  included  studies
ccording  to  Cochrane  Review’s  Handbook  5.0.129 and
valuation  standard  of  case—control  study  suggested  by
ells  G.,30 we  used  ‘‘Newcastle—Ottawa  Quality  Assessment
cale:  Case  Control  Studies’’  (NOS)  to  assess  the  quality  of
ncluded  studies  in  items  such  as  selection  of  study  groups,
omparability  of  their  cases  and  controls,  and  the  exposure
n  cases  and  controls.  When  conforming  to  the  criteria  for  an
tem,  a  study  would  get  one  star  and  result  in  a  maximum
ine  stars.  Studies  that  received  more  than  six  stars  were
onsidered  as  high  quality,  analogous  to  other  reviews.31,32
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e  speciﬁcally  classiﬁed  studies  at  elevated  risk  of  bias  (1—3
tars),  intermediate  risk  of  bias  (4—5  stars),  or  low  risk  of
ias(6—9  stars).  As  this  study  focused  on  the  phlegm  syn-
rome  of  angina,  we  explained  the  ‘‘no  history  of  disease
endpoint)’’  item  as  ‘‘no  history  of  phlegm  turbidity  symp-
om  of  angina  pectoris.’’  Furthermore,  we  created  a  funnel
lot  to  analyze  potential  publication  bias.
ata  synthesis
he  Revman  5.2.6  software  provided  by  ‘‘The  Cochrane  Col-
aboration’’  was  used  to  analyze  the  collected  data.  SMD
ith  its  95%  CI  were  used  to  assess  the  association  between
iomarkers  and  the  phlegm  syndrome  of  angina.  Hetero-
eneity  was  assessed  by  the  Q-statistic  test  and  I2 statistic.33
nter-studies  heterogeneity  was  considered  to  be  signiﬁcant
nder  the  condition  of  P  value  <0.05  with  I2 value  >50%.34
hen  heterogeneity  was  absent,  a  ﬁxed-effects  model  of
he  inverse  variance  method  was  used  to  calculate  pooled
MD.  Otherwise,  a  random-effects  model  was  taken.
ubgroup  analysis  and  investigation  of  heterogeneity
he  subgroup  analysis  was  established  according  to  the  sam-
le  size  proportion  between  the  test  group  and  the  control
roup  (T/C  >  1/4  vs.  T/C  <  1/4).  And  the  between-studies
eterogeneity  was  investigated  through  reevaluation  of  the
riginal  literature  and  data.  Initially,  we  planned  to  explore
opulation-level  variables:  geographic  latitude  (north  vs.
outh)  and  the  mean  age;  and  then  the  following  study-
evel  variables  were  investigated:  year,  total  sample  size,
ample  size  of  the  experimental  group,  sample  size  of  the
ontrol  group,  angina  type  (stable  vs.  unstable  vs.  both),  dif-
erent  diagnostic  criteria  of  angina  pectoris,  number  of  TCM
yndrome,  the  characteristic  of  TCM  syndrome  (deﬁciency
yndrome  vs.  sthenia  syndrome),  type  of  TCM  syndrome
e.g.,  QSS,  blood  stasis  syndrome,  qi  deﬁciency  syndrome,
nd  so  on).  When  necessary,  the  sub-subgroup  analysis  was
uilt  on  the  basis  of  probable  resource  of  heterogeneity
aused  by  different  syndromes  contained  in  the  non-phlegm
urbidity  group.
ensitivity  analysis
o  inspect  the  stability  of  the  results,  sensitivity  analysis  was
onstructed  by  using  two  different  effect  models.
esults
esults  of  the  search
otally,  2152  references  were  retrieved,  among  which  2047
ere  in  Chinese  and  105  in  English.  After  ruling  out  the  arti-
les  that  were  obviously  unrelated  to  the  study  and  repeated
nes,  75  were  left,  including  two  in  English.  Among  them,  64
rticles  were  excluded  through  intensive  screening  for  not
eeting  the  inclusion  criteria.  This  systematic  review  even-
ually  yielded  11  original  documents,  all  in  Chinese  (Table  2).
ig.  1  shows  the  process  of  study  selection.
d
(
t
iD.  Kong  et  al.
isk  of  bias  in  included  studies
e  assumed  studies  that  received  more  than  six  stars  on  the
OS  criteria  to  be  of  high  quality.  The  average  value  of  the
ncluded  studies  was  seven  stars  indicating  superior  quality
vidence  (Table  3).
xposure  results
he  exposure  results  are  pooled  in  Table  4.
ontained  TCM  syndromes  list
CM  syndromes  involved  in  the  non-phlegm  turbidity  group
re  pooled  in  Table  5.
riglyceride
he  outcome  showed  that  the  ‘‘T/C  >  1/4  subgroup’’  had
igniﬁcant  heterogeneity  (X2:  145.13,  df:  7,  P  >  0.00001,  I2:
5%).  We  discovered  that  the  difference  of  the  non-phlegm
urbidity  group  composition  in  these  studies16—18,20,21,23,25,26
as  distinct  from  reviewing  of  the  original  data  and
hus  divided  studies  into  two  sub-subgroups:  Yang  deﬁ-
iency  syndrome  (YDS)  included  in  T/C  >  1/4  subgroup
ersus  non-YDS  in  T/C  >  1/4  subgroup.  The  SMDs  indicate
hat  triglyceride  (TG)  levels  in  the  test  group  is  higher
han  that  of  control  group  for  ‘‘T/C  <  1/4  subgroup’’  and
‘YDS  included  in  T/C  >  1/4  subgroup’’  (SMD:  2.90,  95%  CI:
.50—3.31;  SMD:  1.38,  95%  CI:  1.07—1.69).  For  the  non-YDS
ubgroup,16,17,21,23,25,26 the  heterogeneity  was  signiﬁcant  as
ell  (X2:  12.23,  df:  5,  P:  0.03,  I2:  59%).  Studies  were  clas-
iﬁed  into  two  categories  (CCS  included  vs.  non-CCS).  The
MD  of  ‘‘CCS  included  in  non-YDS’’  sub-subgroup  showed
hat  TG  levels  in  the  test  group  were  higher  compared  with
he  control  group  (SMD:  0.56,  95%  CI:  0.30—0.81);  however,
he  diamond  crossed  the  middle  line  (SMD:  0.07,  95%  CI:
0.18—0.32)  in  ‘‘non-CCS  in  non-YDS’’  sub-subgroup.  The
etails  are  given  in  Fig.  2.
otal  cholesterol
or  ‘‘T/C  <  1/4  subgroup,’’22,24 the  SMD  manifested  that
otal  cholesterol  (TC)  levels  in  the  test  group  was  higher
ompared  with  the  control  group  in  Fig.  3  (SMD:  0.62,  95%
I:  0.32—0.91).  The  heterogeneity  evaluation  turned  out  to
e  signiﬁcant  in  the  ‘‘T/C  >  1/4  subgroup’’  (X2:  99.66,  df:
,  P  >  0.00001,  I2:  92%).  The  sub-subgroup  analysis  was  com-
leted  in  accordance  with  YDS  comprised.  For  ‘‘YDS  included
n  T/C  >  1/4  subgroup,’’18,20 heterogeneity  concluded  to  be
emarkable  (X2:  14.03,  df:  1,  P:  0.0002,  I2:  93%)  so  as  to
andom-effects  model  was  used  (Fig.  4).
The  heterogeneity  of  ‘‘non-YDS  included  in  T/C  >  1/4  sub-
roup’’16,17,19,21,23,25,26 also  turned  out  to  be  signiﬁcant  (X2:
7.28,  df:  6,  P:  0.008,  I2: 65%).  Hence,  the  studies  were
ivided  in  terms  of  whether  Qi  and  yin  deﬁciency  syndrome
QYDS)  was  contained.  As  is  shown  in  Fig.  5,  the  TC  levels  in
est  group  were  higher  than  that  in  control  group  in  ‘‘QYDS
ncluded  in  non-YDS  group’’  (SMD:  0.61,  95%  CI:  0.35—0.87);
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Table  2  Description  of  included  studies.
First  author Year Region Type  of  angina Age  No.  of  cases No.  of  controls No.  of  male No  .of  female Diagnostic  criteria
Zhao  GH16 2009  Liaoning  Stable  &  unstable 48—78 31  119  72  78  WMDC-C
TCMDC-B
Feng JX17 2009  Guangdong  Stable  57.7  ±  11.5 30  60  38  52  WMDC-C
TCMDC-A
Kong SY18 2006  Henan  Stable  &  unstable 40—85 39  107  84  23  WMDC-A
TCMDC-B
Li LM19 2011  Guangdong  Stable  &  unstable 40—79 20  69  53  36  TCMDC-A
Lin Q20 2007  Beijing  Unstable  32—70  29  84  68  45  WMDC-C
TCMDC-C
Liu L21 2009  Sichuan  Unstable  45—90  24  65  31  58  WMDC-D
TCMDC-B
Xie HB22 2003  Hunan  Stable  &  unstable  65.52  ±  9.92  26  134  66  94  WMDC-A
TCMDC-A
Xin YR23 2010  Jiangsu  Stable  &  unstable  67.43  ±  8.81  25  66  65  26  WMDC-A
TCMDC-A
Yan XK24 2006  Heilongjiang  Stable  &  unstable  45—78  30  130  82  78  WMDC-A
TCMDC-A
Zhang BB25 2006  Jiangsu  Stable  &  unstable  33—87  31  90  91  30  WMDC-A
TCMDC-A
Wu YX26 2001  Hubei  Stable  &  unstable  66.9  37  37  52  22  WMDC-A
TCMDC-A
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he  two  groups  performed  equally  in  ‘‘non-QYDS  in  non-YDS
ubgroup’’  (SMD:  0.05,  95%  CI:  −0.17—0.27).
ow-density  lipoprotein-cholesterol
dditionally,  sub-subgroup  analysis  was  accomplished
ccording  to  ‘‘YDS  included  in  T/C  >  1/4  subgroup’’  and
‘non-YDS  included  in  T/C  >  1/4  subgroup’’  on  account  of
he  signiﬁcant  heterogeneity  (X2:  46.80,  df:  7,  P  >  0.00001,
2:  85%).  For  non-YDS  included  subgroup,  the  subset  analy-
is  was  performed  in  that  whether  the  QYDS  was  contained
ecause  of  signiﬁcant  heterogeneity  (X2: 14.69,  df:  3,  P:
.002,  I2:  80%;  X2:  17.36,  df:  5,  P:  0.004,  I2:  71%).  Low-
ensity  lipoprotein-cholesterol  (LDL-C)  levels  in  the  test
roup  proved  to  be  exceeding  that  of  the  control  group
7
y
T
( screening  process.
n  subgroups  except  for  the  ‘‘non-QYDS  in  non-Yang  deﬁ-
iency’’  sub-subgroup  (SMD:  0.12,  95%  CI:  −0.13—0.37)  from
ig.  6.
igh-density  lipoprotein-cholesterol
t  is  shown  in  Fig.  6  that  the  middle  line  intersects
he  diamond  of  the  T/C  <  1/4  subgroup  (SMD:  −0.26,  95%
I:  −0.55—0.03).  Heterogeneity  of  ‘‘T/C  >  1/4  subgroup’’
roved  to  be  signiﬁcant  (X2: 25.80,  df:  7,  P:  0.0005,  I2:
3%)  and  consequently  lead  to  further  sub-subgroup  anal-
sis  demonstrated  in  line  with  whether  YDS  was  embraced.
he  SMDs  indicated  that  high-density  lipoprotein-cholesterol
HDL-C)  levels  in  the  test  group  was  lower  than  that  in  the
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Table  3  Assessment  of  study  quality.
First  author  Year  Selection  Comparability  Exposure  Total
Zhao  GH16 2009  3  1  2  7
Feng JX17 2009  3  1  2  7
Kong SY18 2006  3  1  2  7
Li LM19 2011  3  1  2  7
Lin Q20 2007  3  1  2  7
Liu L21 2009  3  1  2  7
Xie HB22 2003  3  1  2  7
Xin YR23 2010  3  1  2  7
Yan XK24 2006  3  1  2  7
Zhang BB25 2006  3  1  2  7
Wu YX26 2001  3  1  2  7
Note: Selection contains four criteria: (1) Is the case deﬁnition adequate? (2) Representativeness of the cases, (3) selection of controls,
(4) deﬁnition of controls; comparability means comparability of case
contains three criteria: (1) Ascertainment of exposure, (2) same metho
Table  4  Exposure  results.
First  author Year TG  TC  LDL  HDL
Zhao  GH16 2009  +  +  +  +
Feng JX17 2009  +  +  +  +
Kong SY18 2006  +  +  +  +
Li LM19 2011  −  +  +  −
Lin Q20 2007  +  +  +  +
Liu L21 2009  +  +  +  +
Xie HB22 2003  +  +  +  +
Xin YR23 2010  +  +  +  +
Yan XK24 2006  +  +  +  +
Zhang BB25 2006  +  +  +  +
Wu YX26 2001  +  +  +  +
c
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P
Note: ‘‘+’’ means exposed; ‘‘−’’ means not exposed.
A
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Table  5  TCM  syndromes  results.
First  author  Year  TCM  syndrome
QSS  CCS  QYDS  HKYIDS  
Zhao  GH16 2009  +  +  +  +  
Feng JX17 2009  +  −  −  −  
Kong SY18 2006  −  −  −  −  
Li LM19 2011  −  −  −  −  
Lin Q20 2007  +  +  +  +  
Liu L21 2009  +  +  +  +  
Xie HB22 2003  −  +  +  −  
Xin YR23 2010  −  −  +  −  
Yan XK24 2006  +  +  +  +  
Zhang BB25 2006  −  −  −  +  
Wu YX26 2001  +  +  −  −  
Note: QSS: Qi stagnation syndrome; CCS: Cold coagulating syndrome; 
deﬁciency syndrome; HKYADS: heart kidney-yang deﬁciency syndrome
stasis; FAHS: syndrome of ﬁre attacking the heart; HBSS: heart blood st
included; ‘−’ means not included.s and controls on the basis of the design or analysis; exposure
d of ascertainment for cases and controls, (3) non-response rate.
ontrol  group  (SMD:  −0.96,  95%  CI:  −1.28  to  −0.63;  SMD:
0.22,  95%  CI:  −0.41  to  −0.03).
ensitivity  analysis
he  Random  effects  model  was  used  to  evaluate  the  studies,
s  is  provided  in  Table  6. Taking  different  diagnostic  criteria
f  angina  pectoris  in  consideration,  we  play  sensitivity  anal-
sis  through  removing  a  study  which  has  different  diagnostic
riteria  with  others  in  the  same  subgroup  as  well.  The  result
howed  no  signiﬁcant  difference  and  is  presented  in  Table  7.
ublication  bias  assessments  is  shown  in  Figs.  7  and  8, the  funnel  graphic  is  almost
ymmetrical,  suggesting  no  publication  bias  of  the  included
tudies.
HKYADS  YDS  QDBSS  FAHS  HBSS  HQDS
+  −  −  −  +  −
−  −  −  −  +  −
−  +  −  −  +  −
−  −  −  −  +  −
−  +  +  −  +  −
+  −  −  −  +  −
−  +  −  +  +  −
−  −  +  −  +  −
−  +  +  −  +  −
−  −  −  −  +  −
−  −  −  −  +  −
QYDS: Qi and yin deﬁciency syndrome; HKYIDS: heart kidney-yin
; YDS: Yang deﬁciency syndrome; QDBS: Qi deﬁciency and blood
asis syndrome; HQDS: heart Qi deﬁciency syndrome. ‘‘+’’ means
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Figure  2  Meta-analysis  of  triglyceride.
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or  TG,  only  the  diamond  of  the  non  CCS-non  YDS
ubgroup17,23,25 passed  through  the  median  line,  indicating
hat  TG  level  in  the  experimental  group  and  the  control
roup  showed  no  statistical  difference.  However,  TG  levels
n  the  phlegm  syndrome  group  were  higher  compare  with  the
on-phlegm  syndrome  group  in  the  rest  of  the  subgroups.
o  statistically  meaningful  difference  existed  between  the
est  group  and  control  group  for  TC  and  LDL-C  levels  in  non-
YDS-non-YDS  subgroup,  whereas  the  two  biotic  indicators
l
Q
o
wanalysis  of  total  cholesterol.
n  the  test  group  were  higher  than  that  in  the  non-phlegm
yndrome  group  in  other  subgroups.  By  reading  primeval
iterature,  we  found  that  the  non-phlegm  syndrome  group
f  these  studies  was  consisted  by  QSS,  heart  blood  stasis
yndrome  (HBSS),  and  CCS.  This  result  declared  that  when
omparing  with  these  TCM  syndromes  with  sthenia  nature,
o  obvious  difference  was  shown  for  TG,  TC,  and  LDL-C
evels.  Nevertheless,  for  asthenia  syndromes  such  as  YDS,
YDS,  and  HQDS,  the  difference  proved  to  be  signiﬁcantly
bvious.  Furthermore,  HDL-C  levels  of  the  phlegm  group
ere  lower  than  that  of  non-phlegm  group  in  all  subgroups.
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Figure  4  ‘‘YDS  included  in  T/C  >  1/4  subgroup’’  analysis  of  total  cholesterol.
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vFigure  5  ‘‘Non-YDS  included  in  T/C  >  
In  this  study,  we  regarded  phlegm  syndrome  as  the  test
group  and  took  non-phlegm  syndrome  as  the  control  group.
The  non-phlegm  syndrome  group  included  a  variety  of  TCM
syndromes.  Thus,  in  order  to  ensure  the  integrity  of  the
data,  we  apply  the  translated  formula  to  calculate  the  com-
bined  mean  value  and  standard  deviation  value.  After  the
combination,  the  case  number  in  the  control  group  was  sig-
niﬁcantly  greater  than  that  of  the  control  group.  According
to  the  individual  matching  principle  of  the  case—control
study,35 it  makes  slight  sense  to  effect  which  the  propor-
tion  between  the  case  number  of  the  test  group  and  control
group  less  than  1/4(T/C  <  1/4).  Therefore,  subgroup  analysis
was  carried  out  according  to  the  case  number  proportion.
The  NOS  scale  was  utilized  to  appraise  the  quality  of  the
researches,  and  the  score  was  seven  stars  in  all  studies,  thus
indicating  that  the  results  of  this  study  had  credibility  to
some  extent.What’s  new:  The  systematic  review  focus  on  risk  factors
of  angina  pectoris  has  already  existed,  well  meta-analysis
on  risk  factors  of  certain  TCM  syndrome  of  angina  pectoris
has  not  yet.  A  number  of  studies  on  risk  factors  for  TCM
c
e
p
pubgroup’’  analysis  of  total  cholesterol.
yndromes  of  CHD  have  existed,36—38 but  no  with  consen-
us.  Moreover,  the  systematic  review  about  this  topic  is
nprecedented.  It  is  acknowledged  that  phlegm  turbidity
s  the  pathological  production  due  to  spleen  deﬁciency  and
ysfunctional  transportation  of  the  moisture.15 Patients  with
hlegm  turbidity  syndrome  were  obese  and  physically  heavy
nd  sleepy,  which  is  similar  to  patients  with  hyperlipidemia.
n  recent  years,  more  and  more  studies  have  investigated
he  treatment  of  CHD  from  the  perspective  of  strengthen-
ng  spleen  and  removing  phlegm  which  showed  a  noteworthy
ffect.39—41 Blood  lipids  as  the  customary  risk  factors  for  CHD
ave  been  widely  recognized.  This  study  explored  the  cor-
elations  between  blood  lipids  and  phlegm  syndrome  of  CHD
oping  for  offer  corroborative  evidence  for  the  theory  of
reating  CHD  through  adjusting  the  spleen  function  from  the
iew  of  etiology.
The  theory  of  ‘‘treating  before  disease  attack’’  in  TCM
oincides  with  modern  preventive  medicine.  This  study
xplored  risk  factors  for  the  phlegm  syndrome  of  CHD  and
rovided  new  ideas  for  the  prevention  of  CHD  in  a  sense.  If
revention  and  treatment  can  be  earlier  undertaken  based
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Figure  6  Meta-analysis  of  LDL-C.
Figure  7  Meta-analysis  of  HDL-C.
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Table  6  Sensitivity  analysis  1.
Exposure  Subgroup  Pool  SMD  (95%  CI)  P  value  for  Z  test  I2 for  heterogeneity  (%)  P  value  for  heterogeneity  df
TG T/C  <  1/4  subgroup  1.38  (1.07,  1.69)  <0.00001  0  0.52  1
YDS included  in  T/C  >  1/4  subgroup  2.91  (2.37,  3.46)  <0.00001  44  0.18  1
CCS included  in  non-YDS  sub-subgroup  0.56  (0.30,  0.81)  <0.0001  0  0.40  2
Non-CCS in  non-YDS  subgroup  0.08  (−0.25,  0.40)  0.65  39  0.19  2
TC T/C <  1/4  subgroup 0.62  (0.32,  0.91) <0.0001  0  0.45  1
QYDS included  in  non-YDS  group  0.61  (0.35,  0.87)  <0.00001  0  0.41  2
Non-QYDS in  non-YDS  subgroup  0.06  (−0.23,  0.36)  0.04  42  0.16  3
LDL-C T/C <  1/4  subgroup  0.82  (0.52,  1.11)  <0.00001  0  0.36  1
YDS included  in  T/C  >  1/4  subgroup  1.49  (1.09,  1.90)  <0.00001  34  0.22  1
QYDS in  non-Yang  deﬁciency  subgroup 0.87  (0.61,  1.13) <0.00001 0  0.92 2
Non-QYDS in  non-YDS  subgroup 0.12  (−0.13,  0.37) 0.33 0  0.67  2
HDL-C T/C <  1/4  subgroup  −0.26  (−0.55,  0.03)  0.08  0  0.44  1
YDS included  in  T/C  >  1/4  subgroup  −0.96  (−1.28,  −0.63)  <0.00001  0  0.45  1
Non-YDS included  in  T/C  >  1/4  subgroup  −0.18  (−0.40,  0.05)  0.13  40  0.14  5
Table  7  Sensitivity  analysis  2.
Exposure  Subgroup  Pool  SMD  (95%  CI)  P  value  for  Z  test  I2 for  heterogeneity  (%)  P  value  for  heterogeneity  df
TG T/C  <  1/4  subgroup  1.38  (1.07,  1.69)  <0.00001  0  0.52  1
YDS included  in  T/C  >  1/4  subgroup  2.65  (2.09,  3.20)  <0.00001  —  —  0
CCS included  in  non-YDS  sub-subgroup  0.45  (0.15,  0.75)  0.03  0  0.72  1
Non-CCS in  non-YDS  subgroup  −0.01  (−0.47,  0.46)  0.98  57  0.13  1
TC T/C <  1/4  subgroup  0.62  (0.32,  0.91)  <0.0001  0  0.45  1
QYDS included  in  non-YDS  group  0.50  (0.20,  0.81)  0.001  0  0.83  1
Non-QYDS in  non-YDS  subgroup  −0.03  (−0.29,  0.23)  0.82  46  0.16  2
LDL-C T/C <  1/4  subgroup  0.82  (0.52,  1.11)  <0.00001  0  0.36  1
YDS included  in  T/C  >  1/4  subgroup 1.29  (0.84,  1.75)  <0.00001  —  —  0
QYDS in  non-Yang  deﬁciency  subgroup  0.87  (0.56,  1.18)  <0.00001  0  0.69  1
Non-QYDS in  non-YDS  subgroup 0.08  (−0.23,  0.38)  0.63  0  0.48  1
HDL-C T/C <  1/4  subgroup  −0.26  (−0.55,  0.03)  0.08  0  0.44  1
YDS included  in  T/C  >  1/4  subgroup  −0.82  (−1.30,  −0.35)  <0.0007  —  —  0
Non-YDS included  in  T/C  >  1/4  subgroup  −0.22  (−0.41,  0.03)  0.02  47  0.11  4
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1igure  8  Posted  bias  assessment  of  the  collected  studies.
n  the  risk  factors,  as  the  theory  always  emphasized  in  TCM—
treating  before  disease  attack,  the  results  of  our  study
ight  have  profound  clinical  and  public  health  signiﬁcance.
imitation
his  study  has  several  limitations.  First,  the  measuring
nstruments  of  the  biomarkers  in  these  studies  cannot  be
uaranteed  to  be  exactly  the  same,  therefore,  method-
logical  heterogeneity  might  be  caused  by  different  tools.42
econd,  the  mean  value  and  standard  deviation  value  of  the
ontrol  group  were  translated  according  to  the  formula  on
ccount  of  ﬁrst-hand  data  not  obtainable,  which  may  cause
ias.  Third,  the  effect  is  not  meaningful  for  studies  of  which
he  case  number  proportion  is  <1/4(T/C  <  1/4).  Last  but  not
he  least,  even  though  we  searched  the  authoritative  English
atabase,  no  English  studies  met  the  inclusion  criteria  were
ollected  eventually.  Therefore  publication  bias  may  exist.
onclusion
he  levels  of  TG,  TC,  and  LDL-C  were  demonstrated  to  be
igher  in  phlegm  turbidity  syndrome  when  compared  with
CM  syndromes  with  asthenia  nature  such  as  YDS,  QYDS,  and
QDS.  However,  for  sthenia  syndromes  such  as  QSS,  HBSS,
nd  CCS,  there  was  no  obvious  difference.  Moreover,  HDL-C
evels  of  the  phlegm  turbidity  group  were  lower  than  that
f  the  non-phlegm  group.  Nonetheless,  these  results  should
e  conﬁrmed  with  further  studies.
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